Retatrutide
Triple GLP-1/GIP/glucagon receptor agonist — next-generation metabolic research compound
Mechanism
What is Retatrutide?
Retatrutide is a triple GIP/GLP-1/glucagon receptor agonist currently in Phase 3 clinical trials. It has shown significant weight loss results — up to 24% body weight reduction in Phase 2 trials.
🇬🇧 United Kingdom · MHRA
Legal status
Retatrutide is not licensed by the MHRA for therapeutic use in the UK. It is not a controlled substance under the Misuse of Drugs Act. Legal to purchase for research purposes.
This website is intended for research and educational purposes only. The information provided does not constitute medical advice and should not be used to diagnose, treat, cure, or prevent any condition. Peptides discussed on this site are not approved by the MHRA for human therapeutic use. Always consult a qualified healthcare professional before using any substance.
Full legal guide for United Kingdom →Frequently asked
Common questions
Is retatrutide legal in the UK?
Yes — retatrutide is not a controlled substance under the UK Misuse of Drugs Act and is not licensed by the MHRA for therapeutic use. It can be purchased for legitimate research purposes.
Can I buy retatrutide in the UK?
Retatrutide is available from research peptide vendors that ship to the UK. It is not available from UK pharmacies or on NHS prescription as it has not received MHRA approval.
When will retatrutide be available in the UK?
Retatrutide is in Phase 3 trials as of 2024. If trials succeed, MHRA approval could be sought from 2026–2027. UK availability as a prescription medicine would follow approval, similar to the path tirzepatide (Mounjaro) took.
Where to source Retatrutide
Retatrutide in United Kingdom
We verify COA documentation and purity standards before listing any vendor.
Retatrutide in other markets